GE Healthcare eyeing more cell and gene therapy production tech supplier takeovers

By Gareth Macdonald

- Last updated on GMT


Related tags Stem cell Gene

GE Healthcare has hinted that more gene and cell therapy acquisitions will follow its takeover of the Biosafe Group.

The General Electric (GE) unit announced the acquisition of Biosafe last week​, citing the large number of cell and gene-based cancer therapies being developed as the motivation for the investment.

Switzerland based BioSafe makes single-use cell processing and separation tech at its facility in Eysins.

The firm employs 85 people all of whom “will become GE employees in the Life Sciences cell therapy business​” according to a spokesman.

He cited Biosafe’s portfolio single-use separation kits and its Sepax automated stem cell banking technology as specific drivers for the deal which he said “bring the GE Healthcare portfolio closer to an end-to-end offering for cell therapy workflows​.”

Biosafe diversifies GE’s presence with its leadership in the regenerative and cord blood banking space, as well as access to a broader range of cell types​.”

More takeovers

GE is also on the look for other companies developing technologies for cell and gene therapy firm according to the spokesman.

He told us “this deal gets GE most of the way to end-to-end production of cell therapies for most of the therapies currently under production.

GE will look to innovation partnerships, collaborations, and other growth opportunities to continue filling gaps and work towards the vision of a single-solution workflow for cell therapy​.”

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more